Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of JNJ-81201887 in geographic atrophy secondary to age-related macular degeneration
ISRCTN11083692Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Gene Therapies
01
Overview
Phase 2, open-label trial of JNJ-81201887 in age-related macular degeneration (AMD) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with ocular and systemic treatment-emergent adverse events, Number of participants with abnormal clinical laboratory findings and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
JNJ-81201887
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN11083692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11083692.